27 results on '"Eisenhauer, Elizabeth A."'
Search Results
2. Phase II study of PX-866 in recurrent glioblastoma.
- Author
-
Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR, Eisenstat DD, Kakumanu AS, Salim M, Chalchal H, Squire J, Tsao MS, Kamel-Reid S, Banerji S, Tu D, Powers J, Hausman DF, and Mason WP
- Subjects
- Administration, Oral, Adult, Aged, Brain Neoplasms pathology, Brain Neoplasms radiotherapy, Female, Glioblastoma pathology, Glioblastoma radiotherapy, Gonanes administration & dosage, Humans, Male, Middle Aged, Phosphoinositide-3 Kinase Inhibitors, Treatment Outcome, Antineoplastic Agents therapeutic use, Brain Neoplasms drug therapy, Glioblastoma drug therapy, Gonanes therapeutic use
- Abstract
Background: Glioblastoma (GBM) is the most aggressive malignancy of the central nervous system in adults. Increased activity of the phosphatidylinositol-3-OH kinase (PI3K) signal transduction pathway is common. We performed a phase II study using PX-866, an oral PI3K inhibitor, in participants with recurrent GBM., Methods: Patients with histologically confirmed GBM at first recurrence were given oral PX-866 at a dose of 8 mg daily. An MRI and clinical exam were done every 8 weeks. Tissue was analyzed for potential predictive markers., Results: Thirty-three participants (12 female) were enrolled. Median age was 56 years (range 35-78y). Eastern Cooperative Oncology Group performance status was 0-1 in 29 participants and 2 in the remainder. Median number of cycles was 1 (range 1-8). All participants have discontinued therapy: 27 for disease progression and 6 for toxicity (5 liver enzymes and 1 allergic reaction). Four participants had treatment-related serious adverse events (1 liver enzyme, 1 diarrhea, 2 venous thromboembolism). Other adverse effects included fatigue, diarrhea, nausea, vomiting, and lymphopenia. Twenty-four participants had a response of progression (73%), 1 had partial response (3%, and 8 (24%) had stable disease (median, 6.3 months; range, 3.1-16.8 months). Median 6-month progression-free survival was 17%. None of the associations between stable disease and PTEN, PIK3CA, PIK3R1, or EGFRvIII status were statistically significant., Conclusions: PX-866 was relatively well tolerated. Overall response rate was low, and the study did not meet its primary endpoint; however, 21% of participants obtained durable stable disease. This study also failed to identify a statistically significant association between clinical outcome and relevant biomarkers in patients with available tissue., (© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
3. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.
- Author
-
Tsoref D, Welch S, Lau S, Biagi J, Tonkin K, Martin LA, Ellard S, Ghatage P, Elit L, Mackay HJ, Allo G, Tsao MS, Kamel-Reid S, Eisenhauer EA, and Oza AM
- Subjects
- Adenocarcinoma drug therapy, Administration, Oral, Adult, Aged, Aged, 80 and over, Endometrial Neoplasms pathology, Female, Humans, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local pathology, Sirolimus administration & dosage, Treatment Outcome, Antineoplastic Agents administration & dosage, Carcinoma, Endometrioid drug therapy, Endometrial Neoplasms drug therapy, Neoplasm Recurrence, Local drug therapy, Sirolimus analogs & derivatives, TOR Serine-Threonine Kinases antagonists & inhibitors
- Abstract
Objective: The phosphatidylinositol-3 kinase/serine-threonine kinase PI3K/AKT pathway is postulated to be central to cancer cell development. Activation of this pathway is believed to promote angiogenesis, protein translation and cell cycle progression. A large percentage of endometrial carcinomas have demonstrated mutations within this regulation pathway which result in constitutional activation. The downstream effector protein mammalian target of rapamycin (mTOR) acts as a critical checkpoint in cancer cell cycling and is a logical target for drug development. The efficacy and tolerability of the oral mTOR inhibitor ridaforolimus were evaluated in this study., Methods: This phase II study evaluated the single agent tolerability and activity of oral ridaforolimus administered at a dose of 40mg for 5 consecutive days followed by a 2day break, in women with recurrent or metastatic endometrial carcinoma who had received no chemotherapy in the metastatic setting., Results: 31 of 34 patients were evaluable. Three partial responses (8.8%) were observed with response duration ranging between 7.9 and 26.5months. An additional 18 patients showed disease stabilization (52.9%) for a median duration of 6.6months. Response rates were not affected by previous chemotherapy exposure. No correlation was found between response and mutation status., Conclusion: Oral ridaforolimus was reasonably tolerated and demonstrated modest activity in women with recurrent or metastatic endometrial cancers. Potential synergy between mTOR inhibition, angiogenesis and hormonal pathways warrants ongoing evaluation., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
4. Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.
- Author
-
Robinson AG, Booth CM, and Eisenhauer EA
- Subjects
- Clinical Trials as Topic methods, Disease-Free Survival, Drug Approval, Endpoint Determination, Humans, Treatment Outcome, Antineoplastic Agents therapeutic use, Neoplasms drug therapy
- Abstract
Progression-free survival (PFS) is an end-point in an increasing number of cancer clinical trials, informing both regulatory bodies and clinical practice. PFS is utilised both as a surrogate end-point for overall survival and as a primary trial end-point in itself. Understanding the history of clinical trial definitions of progression provides some context for how PFS may be applied to clinical practice as well as some of its limitations that need to be considered in patient care decisions. This commentary reviews recent drug approval for anti-cancer agents in solid tumours, reviews various concepts of progression in clinical trials and outlines some future directions for patient care and clinical trial research using progression free survival., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
5. Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practice.
- Author
-
Robinson AG, Booth CM, and Eisenhauer EA
- Subjects
- Disease-Free Survival, Drug Approval, Endpoint Determination, Humans, Treatment Outcome, Antineoplastic Agents therapeutic use, Neoplasms drug therapy
- Abstract
Disease-free survival (DFS) is an end-point for an increasing number of clinical trials in adjuvant and curative intent cancer treatment informing both regulatory bodies and clinical practice. DFS is seen both as a surrogate end-point and as an end-point in itself in clinical trials. Understanding the history of DFS, and some of the assumptions, limitations, and vulnerabilities for studies designed with this primary end-point are required. This commentary reviews recent drug approvals for anti-cancer agents in solid tumours in the adjuvant and curative settings, and considers the meaning of DFS from the perspectives of clinical trials and clinical practice., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
6. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
- Author
-
Goodwin RA, Jamal R, Tu D, Walsh W, Dancey J, Oza AM, Elit L, and Eisenhauer EA
- Subjects
- Adenocarcinoma drug therapy, Adenocarcinoma metabolism, Adenocarcinoma pathology, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor metabolism, Carcinoma, Adenosquamous drug therapy, Carcinoma, Adenosquamous metabolism, Carcinoma, Adenosquamous pathology, Disease Progression, Drug Administration Schedule, Endometrial Neoplasms metabolism, Endometrial Neoplasms pathology, Female, Humans, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local pathology, Retrospective Studies, Sirolimus adverse effects, Sirolimus therapeutic use, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Endometrial Neoplasms drug therapy, Neoplasm Recurrence, Local drug therapy, Sirolimus analogs & derivatives
- Abstract
Objective: Temsirolimus (TEM) has recently shown activity (NCIC CTG phase II trial) in endometrial cancer (EC). Despite EC having a high rate of PTEN mutation, in this trial activity was independent of PTEN and other molecular markers. We explored whether treatment related toxicity occurring in cycle one was predictive of outcomes., Methods: Patients were those enrolled on two sequential phase II studies of the NCIC CTG that evaluated single agent TEM in women with recurrent or metastatic chemotherapy naïve or treated EC. An exploratory landmark analysis examined the relationship between early treatment related toxicities as well as prior chemotherapy and efficacy outcomes (response, progression, and tumor size shrinkage) in univariate and multivariate analyses. The relationship between molecular markers and outcomes was also reexamined in patients., Results: Mucositis, diarrhea, decreased absolute neutrophil count, as well as elevated glucose, or cholesterol were not independent predictors of response or progression. Highest fasting triglyceride predicted for a 3.5% tumor shrinkage from baseline. Women previously treated with chemotherapy were at 7.37 times greater risk of progression and experienced 20.9% increased tumor growth compared to chemotherapy naïve women. Molecular markers were not predictors of response or progression., Conclusions: Except for elevation in fasting triglyceride being associated with minimal tumor shrinkage, no other relationship between efficacy and TEM induced adverse events was found. mTOR inhibition activity in EC seems greatest in chemo-naïve patients. Future studies of mTOR inhibitors in EC should focus on women without prior chemotherapy while continuing to explore molecular mechanisms of benefit., (© 2013.)
- Published
- 2013
- Full Text
- View/download PDF
7. Targeted agents: how to select the winners in preclinical and early clinical studies?
- Author
-
Goodwin R, Giaccone G, Calvert H, Lobbezoo M, and Eisenhauer EA
- Subjects
- Animals, Antineoplastic Agents administration & dosage, Clinical Trials, Phase II as Topic, Drug Design, Health Planning Guidelines, Humans, Mice, Models, Animal, Antineoplastic Agents pharmacokinetics, Clinical Trials, Phase I as Topic methods, Drug Evaluation, Preclinical methods, Neoplasms drug therapy, Therapies, Investigational methods
- Abstract
There has been a significant shift within oncology drug development away from empiric screening of cytotoxic compounds to the era of genomics and molecularly targeted agents. The drug development process is evolving with greater emphasis on proof-of-mechanism studies in both preclinical and early clinical development. The Methodology for the Development of Innovative Cancer Therapies (MDICT) Task Force, established as a forum for academic and pharmaceutical leaders to discuss methodological issues in targeted anticancer therapy development, met in March 2010 to review what were the minimal data required to make appropriate decisions about moving new targeted cancer agents from late preclinical development into phase I and from phase I into phase II trials. A number of specific questions were posed, and responses to each developed through survey, literature review and discussion at the face to face meeting of the MDICT Task Force. Consensus emerged around the necessity to demonstrate proof-of-mechanism and obtain information on key pharmacokinetic aspects of drug behaviour in late preclinical and early clinical trials. However, controversy remains on the extent of in vivo anti-tumour efficacy required to support clinical development of targeted agents. A systematic review of the data in this area would be informative. Further, while objective response in phase I trials may be a favourable signal about the potential activity of a new agent, debate exists around the weight that should be placed on the observation of stable disease or functional imaging changes in driving drug development decisions in the absence of observing either responses or convincing pharmacodynamic data in phase I. MDICT made a number of recommendations that may aid in future development of targeted agents., (Copyright © 2011. Published by Elsevier Ltd.)
- Published
- 2012
- Full Text
- View/download PDF
8. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.
- Author
-
Mackay HJ, Tinker A, Winquist E, Thomas G, Swenerton K, Oza A, Sederias J, Ivy P, and Eisenhauer EA
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Indoles adverse effects, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Pyrroles adverse effects, Sunitinib, Uterine Cervical Neoplasms pathology, Antineoplastic Agents therapeutic use, Indoles therapeutic use, Pyrroles therapeutic use, Uterine Cervical Neoplasms drug therapy
- Abstract
Objective: Vascular endothethial growth factor (VEGF) and stem cell factor (c-KIT) signaling may play a role in the development and progression of cervical carcinoma. Sunitinib malate is an oral, multi-targeted tyrosine kinase inhibitor that inhibits receptors for VEGF, c-Kit and platelet-derived growth factor. This multi-centre phase II study was performed to evaluate the activity of sunitinib in women with locally advanced or metastatic cervical carcinoma who had received up to one prior line of chemotherapy for advanced disease., Methods: Sunitinib, 50 mg/day, was administered in 6-week cycles (4 weeks on followed by 2 weeks off treatment). The primary endpoint was the objective response rate., Results: Sixteen (84%) of 19 patients enrolled had stable disease (median duration 4.4 months, 2.3-17 months), but no objective response was observed. Median time to progression was 3.5 months (range, 2.7-7.0 months). Four patients had fistulae develop on study treatment and an additional patient developed a fistula 3.5 months after discontinuation of therapy. All five patients had received either prior chemoradiation or radiation., Conclusions: A higher rate of fistula formation (26.3%) was observed than would be expected and is of concern. Sunitinib has insufficient activity as a single agent in cervical cancer to warrant further investigation., (Copyright 2009 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
9. Call for clarity in the reporting of benefit associated with anticancer therapies.
- Author
-
Booth CM, Ohorodnyk P, and Eisenhauer EA
- Subjects
- Antineoplastic Agents adverse effects, Clinical Trials as Topic, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Deoxycytidine analogs & derivatives, Fluorouracil administration & dosage, Fluorouracil adverse effects, Humans, Neoplasms mortality, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms mortality, Sensitivity and Specificity, Survival Analysis, Total Quality Management, Treatment Outcome, Gemcitabine, Antineoplastic Agents administration & dosage, Editorial Policies, Neoplasms drug therapy, Periodicals as Topic
- Published
- 2009
- Full Text
- View/download PDF
10. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
- Author
-
Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, and Fyles A
- Subjects
- Adenocarcinoma secondary, Adult, Aged, Carcinoma, Adenosquamous secondary, Endometrial Neoplasms secondary, Erlotinib Hydrochloride, Female, Humans, Middle Aged, Adenocarcinoma drug therapy, Antineoplastic Agents therapeutic use, Carcinoma, Adenosquamous drug therapy, Endometrial Neoplasms drug therapy, Neoplasm Recurrence, Local drug therapy, Quinazolines therapeutic use
- Abstract
Purpose: Epidermal growth factor receptor (EGFR) overexpression is common in endometrial cancers and may have a major role in tumor growth and progression. Erlotinib is an orally active, selective inhibitor of EGFR tyrosine kinase activity., Patients and Methods: A multinomial design two-stage phase II study was performed to evaluate single-agent activity of erlotinib in women with advanced endometrial cancer with recurrent or metastatic disease who were chemotherapy naïve and had received up to one line of prior hormonal therapy. Erlotinib was administered at daily dose of 150 mg. Archival tumor tissue was analyzed for EGFR expression by immunohistochemistry (IHC) and gene amplification by fluorescent in situ hybridization (FISH). Mutational status of EGFR was determined in responders., Results: Thirty-two of 34 entered patients are assessable for response. Treatment was well tolerated and severe toxicity infrequent, with the only grade 4 toxicity being an elevation of transaminases (AST). There were four confirmed partial responses (PRs; 12.5%; 95% CI, 3.5% to 29%) lasting 2 to 36 months. Fifteen patients had stable disease (SD), with median duration of 3.7 months (range, 2 to 12 months). EGFR expression was analyzed in thirty patients; 19 were positive, nine were negative, and two were not assessable. Of the 19 patients who were EGFR positive, three had PR (16%), seven SD, and eight progressive disease, and one was not assessable. No mutations were identified in responders. FISH showed no correlation of response with gene amplification., Conclusion: Erlotinib is well tolerated with an overall objective response rate of 12.5%. Molecular analysis did not identify EGFR mutations in responders or correlation of response with gene amplification.
- Published
- 2008
- Full Text
- View/download PDF
11. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
- Author
-
Lee CW, Bélanger K, Rao SC, Petrella TM, Tozer RG, Wood L, Savage KJ, Eisenhauer EA, Synold TW, Wainman N, and Seymour L
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacokinetics, Benzamides adverse effects, Benzamides pharmacokinetics, Disease Progression, Drug Delivery Systems, Female, Humans, Kinesins antagonists & inhibitors, Male, Middle Aged, Mucous Membrane drug effects, Mucous Membrane pathology, Neoplasm Metastasis, Neoplasm Recurrence, Local, Quinazolines adverse effects, Quinazolines pharmacokinetics, Treatment Outcome, Antineoplastic Agents therapeutic use, Benzamides therapeutic use, Eye Neoplasms drug therapy, Melanoma drug therapy, Quinazolines therapeutic use, Skin Neoplasms drug therapy
- Abstract
To assess the response rate and toxicity of the kinesin spindle protein (KSP) inhibitor, ispinesib, in malignant melanoma. Seventeen patients were enrolled from April to November 2005. Ispinesib was administered as a 1-hour infusion at a dose of 18 mg/m2 once every 3 weeks until disease progression. No objective responses were seen. Six patients (35%) had a best response of stable disease for a median duration of 2.8 months. Disease progression was documented in 9 (53%) after 1 or 2 cycles. Eighty-eight percent of patients received > or =90% of planned dose intensity. Grade 3 non-hematologic toxicities included dizziness (1) and blurred vision (1). There was one episode of febrile neutropenia, but no grade 3 or 4 biochemical adverse events. Pharmacokinetics was consistent with prior studies. KSP immunoreactivity was seen in 14 of 16 available archival tissue samples (88%). Ispinesib can be safely administered using the dose and schedule employed, with mild hematologic and non-hematologic toxicity. No objective responses were observed, and further development of single-agent ispinesib in malignant melanoma is not recommended. Although KSP expression appears to be common in melanoma, KSP may not be a suitable target for its treatment.
- Published
- 2008
- Full Text
- View/download PDF
12. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
- Author
-
El-Maraghi RH and Eisenhauer EA
- Subjects
- Humans, Randomized Controlled Trials as Topic, Research Design, Antineoplastic Agents therapeutic use, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Neoplasms drug therapy
- Abstract
Purpose: Because the appropriate design and end points for phase II evaluation of targeted anticancer agents are unclear, we undertook a review of recent reports of phase II trials of targeted agents to determine the types of designs used, the planned end points, the outcomes, and the relationship between trial outcomes and regulatory approval., Methods: We retrieved reports of single-agent phase II trials in six solid tumors for 19 targeted drugs. For each, we abstracted data regarding planned design and actual results. Response rates were examined for any relationship to eventual success of the agents, as determined by US Food and Drug Administration approval for at least one indication., Results: Eighty-nine trials were identified. Objective response was the primary or coprimary end point in the majority of trials (61 of 89 trials). Fourteen reports were of randomized studies generally evaluating different doses of agents, not as controlled experiments. Enrichment for target expression was uncommon. Objective responses were seen in 38 trials; in 19 trials, response rates were more than 10%, and in eight, they were more than 20%. Agents with high response rates tended to have high nonprogression rates; renal cell carcinoma was the exception to this. Higher overall response rates were predictive of regulatory approval in the tumor types reviewed (P = .005)., Conclusion: In practice, phase II design for targeted agents is similar to that for cytotoxics. Objective response seems to be a useful end point for screening new targeted agents because, in our review, its observation predicted for eventual success. Improvements in design are recommended, as is more frequent inclusion of biological questions as part of phase II trials.
- Published
- 2008
- Full Text
- View/download PDF
13. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
- Author
-
Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, and Eisenhauer EA
- Subjects
- Adult, Aged, Drug Design, Health Planning Guidelines, Humans, Middle Aged, Antineoplastic Agents therapeutic use, Clinical Trials, Phase I as Topic, Neoplasms drug therapy, Therapies, Investigational
- Abstract
Oncology drug development has seen a paradigm shift in the past decade from traditional cytotoxic agents to molecular targeted therapies. Given the different mechanisms and toxicities of these agents, drug development methodology may also require novel approaches. To address emerging issues in oncology drug development the 'Methodology for the Development of Innovative Cancer Therapies' (MDICT) task force was established to provide a forum for academic leaders involved in cancer drug development to discuss methodological issues inherent to the study of targeted anticancer therapy. At the inaugural MDICT meeting in 2006, discussion focused on the most appropriate primary endpoints for first-in-man phase I studies of targeted anticancer agents and organisational issues of such studies. This report summarises the scientific reviews and discussions as well as the recommendations regarding phase I trial design formulated by the MDICT task force.
- Published
- 2008
- Full Text
- View/download PDF
14. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
- Author
-
Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, and Seymour LK
- Subjects
- Drug Design, Health Planning Guidelines, Humans, Antineoplastic Agents therapeutic use, Clinical Trials, Phase II as Topic methods, Neoplasms drug therapy, Therapies, Investigational methods
- Abstract
The Methodology for the Development of Innovative Cancer Therapies (MDICT) task force considered aspects of the design and conduct of phase II studies for molecular targeted agents during their 2007 meeting. The task force recommended that multinomial endpoints and designs should be considered for phase II studies of targeted agents, that both single arm as well as randomised designs remain appropriate in certain settings, and that further assessment of novel endpoints (tumour growth kinetic assessment, biomarker or functional imaging) and designs (randomised discontinuation or Bayesian adaptive design) be encouraged. The MDICT cautioned on the use of small randomised trials which have a number of statistical pitfalls and dangers and strongly encouraged the complete reporting, including negative trials, in the scientific literature.
- Published
- 2008
- Full Text
- View/download PDF
15. Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).
- Author
-
Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, and Eisenhauer EA
- Subjects
- Aged, Antineoplastic Agents adverse effects, Canada, Clinical Trials as Topic, Female, Humans, Male, Middle Aged, Pyridines adverse effects, Ribonucleotide Reductases antagonists & inhibitors, Thiosemicarbazones adverse effects, Treatment Outcome, Antineoplastic Agents therapeutic use, Carcinoma, Renal Cell drug therapy, Kidney Neoplasms drug therapy, Pyridines therapeutic use, Thiosemicarbazones therapeutic use
- Abstract
Triapine is a novel small molecule ribonucleotide reductase inhibitor that showed activity in renal cell carcinoma (RCC) cell lines. Evaluating new agents with novel mechanisms remains of interest for patients with incurable RCC. This was a single-arm, multicentre phase II trial where Triapine was given at a schedule of 96 mg/m2 2-h infusion daily x 4 repeated every 2 weeks in patients with recurrent RCC. A median of four cycles of Triapine was administered to 19 eligible patients. One response was seen (7%.) Median time to progression was 3.6 months. Common adverse events (AEs) were grade 1-2, with fatigue in 74%, nausea in 68% and vomiting in 58%. However grade 3/4 neutropenia was seen in 79% and acute reactions of hypoxia, hypotension, methemoglobinemia were seen. Dose reductions/delays due to AEs were common with only 47% of patients receiving > 90% of planned dose intensity. The study closed, at the end of stage 1 as it did not meet the minimal efficacy criteria to proceed. Further evaluation of Triapine at this dose and schedule in patients with advanced kidney cancer is not recommended.
- Published
- 2007
- Full Text
- View/download PDF
16. Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group.
- Author
-
Kirby S, Gertler SZ, Mason W, Watling C, Forsyth P, Aniagolu J, Stagg R, Wright M, Powers J, and Eisenhauer EA
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacokinetics, Canada, Female, Humans, Male, Middle Aged, Sulfonamides adverse effects, Sulfonamides pharmacokinetics, Treatment Outcome, Antineoplastic Agents administration & dosage, Brain Neoplasms drug therapy, Glioma drug therapy, Sulfonamides administration & dosage
- Abstract
We studied the activity of T138067-sodium in patients with malignant gliomas. T138067-sodium is a unique new chemotherapy agent that inhibits microtubule formation by binding irreversibly and specifically to beta(1), beta(2)and beta(4) isotypes of 3-tubulin, causing cell arrest at G(2)/M and inducing apoptosis. Patients with recurrent anaplastic astrocytoma or glioblastoma multiforme were treated intravenously with 330 mg/m(2) of T138067-sodium weekly. Treatment was continued until the patient experienced either unacceptable toxicity or progressive disease. Patients had to have histologically proven glioma, have bidimensionally measurable disease at least 1 cm x 1 cm, and have received no more than one prior adjuvant chemotherapy. No chemotherapy or radiotherapy for recurrent disease was permitted. Nineteen patients entered the trial. One patient was found to be ineligible. There were two patients with anaplastic astrocytoma and 16 with glioblastoma multiforme. Only two patients had received prior adjuvant chemotherapy. The first seven patients had full pharmacokinetic sampling. No dose-limiting toxicity was seen, and pharmacokinetic results were consistent with those from nonglioma patients. The most common drug-related effects were fatigue (33%), nausea (28%), neutropenia (28%), and anorexia (17%). No patients stopped the study because of toxicity. No responses were seen in the 15 eligible patients who completed at least one cycle. Three patients had stable disease with a median duration of 2.6 months. Our results suggest that given in this dose and schedule T138067-sodium does not have activity in this population of anaplastic astrocytoma and glioblastoma multiforme.
- Published
- 2005
- Full Text
- View/download PDF
17. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
- Author
-
Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, and Eisenhauer EA
- Subjects
- Adult, Aged, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Area Under Curve, Camptothecin administration & dosage, Camptothecin adverse effects, Canada, Drug Administration Schedule, Endpoint Determination, Female, Humans, Infusions, Intravenous, Middle Aged, Antineoplastic Agents therapeutic use, Camptothecin analogs & derivatives, Camptothecin therapeutic use, Neoplasm Recurrence, Local drug therapy, Ovarian Neoplasms drug therapy
- Abstract
Purpose: Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan (GI147211), which demonstrated superior levels of activity compared with topotecan in preclinical models. We studied two schedules of OSI-211 in a randomized design in relapsed ovarian cancer to identify the more promising of the two schedules for further study., Patients and Methods: Eligible patients had measurable epithelial ovarian, fallopian, or primary peritoneal cancer that was recurrent after one or two prior regimens of chemotherapy. Patients were randomly assigned to receive either arm A (OSI-211 1.8 mg/m(2)/d administered by 30-minute intravenous infusion on days 1, 2, and 3 every 3 weeks) or arm B (OSI-211 2.4 mg/m(2)/d administered by 30-minute intravenous infusion on days 1 and 8 every 3 weeks). The primary outcome measure was objective response, which was confirmed by independent radiologic review, and a pick the winner statistical design was used to identify the schedule most likely to be superior., Results: Eighty-one patients were randomized between October 2000 and September 2001. The hematologic toxic effects were greater on arm A than on arm B (grade 4 neutropenia, 51% v 22%, respectively), as was febrile neutropenia (26% v 2.4%, respectively). Of the 80 eligible patients, eight patients (10%) had objective responses; six responders (15.4%; 95% CI, 6% to 30%) were in arm A and two responders (4.9%; 95% CI, 1% to 17%) were in arm B., Conclusion: The OSI-211 daily for 3 days intravenous schedule met the statistical criteria to be declared the winner in terms of objective response. This schedule was also associated with more myelosuppression than the schedule of OSI-211 administered in arm B.
- Published
- 2005
- Full Text
- View/download PDF
18. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma.
- Author
-
Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, Wainman N, Colevas AD, and Eisenhauer EA
- Subjects
- Adult, Aged, Anorexia chemically induced, Antineoplastic Agents adverse effects, Diarrhea chemically induced, Fatigue chemically induced, Female, Flavonoids adverse effects, Humans, Infusions, Intravenous, Male, Maximum Tolerated Dose, Melanoma pathology, Middle Aged, Neoplasm Metastasis, Piperidines adverse effects, Treatment Outcome, Vomiting chemically induced, Antineoplastic Agents therapeutic use, Cyclin-Dependent Kinases antagonists & inhibitors, Flavonoids therapeutic use, Melanoma drug therapy, Piperidines therapeutic use
- Abstract
Purpose: To test the activity of the cyclin dependent kinase (cdk) inhibitor flavopiridol in malignant melanoma, a disease with frequent abnormalities of the cyclin dependent kinase system., Patients and Methods: Patients had histologically proven, unidimensionally measurable malignant melanoma, incurable by standard therapy. Prior adjuvant immunotherapy was allowed, but patients were otherwise untreated for advanced disease. Flavopiridol was administered at a dose of 50 mg/m(2) IV over 1 hour daily x 3 days every 3 weeks. Patients were assessed for response every 2 cycles., Results: 17 patients were accrued over 5 months. No objective responses were documented in the 16 patients evaluable for response. Seven patients (44%) had stable disease after 2 cycles, with a median of 2.8 months (range 1.8-9.2). The most common treatment-related non-hematologic toxicities were diarrhea (82%), nausea (47%), fatigue (41%), anorexia (35%) and vomiting (29%). Most treatment-related toxicities were mild, except for diarrhea (grade 3 in 3 patients, grade 4 in 1 patient), nausea (grade 3 in 1 patient) and tumor pain (grade 3 in 1 patient). Hematologic toxicities were minimal, none worse than grade 2. Eighty-eight percent of patients received >/=90% planned dose intensity; 2 patients had dose reductions for gastrointestinal (GI) toxicity., Conclusions: Flavopiridol is well tolerated at the dose regimen used in this study, with an acceptable (primarily GI) toxicity profile. Although 7 of the 16 patients had stable disease ranging from 1.8 to 9.2 months in duration, there was no evidence of significant clinical activity in malignant melanoma by objective response criteria.
- Published
- 2004
- Full Text
- View/download PDF
19. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice.
- Author
-
Parulekar WR and Eisenhauer EA
- Subjects
- Clinical Trials, Phase II as Topic, Humans, Neoplasms drug therapy, Research Design, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Clinical Trials, Phase I as Topic methods
- Abstract
Background: New targeted, non-cytotoxic anticancer agents, such as small-molecule kinase inhibitors, pose challenges to the current phase I paradigm of dose selection based on toxicity. Moreover, increasing the drug dose to toxicity may be unnecessary for drug effect, making the use of maximum tolerated dose as a surrogate of effective dose inappropriate in the phase I setting. Because little is known about the optimal methods of recommended phase II dose selection of targeted, non-cytotoxic therapies, we reviewed the strategies that were used in completed phase I studies of these drugs., Methods: We retrieved 60 publications of phase I studies involving 31 single agents representative of the most common targets of interest in the oncology literature. For each publication, we abstracted data regarding patient population, starting dose, methods of dose escalation and determination of recommended phase II dose, and inclusion of correlative studies in study conduct., Results: Of the 60 completed phase I studies, 36 used toxicity and eight used pharmacokinetic data as endpoints for selection of the recommended phase II dose. Nontraditional endpoints, such as measures of molecular drug effects in tumor or surrogate tissue or functional imaging studies, were not routinely incorporated into the study design and rarely formed the primary basis for dose selection., Conclusions: To date, phase I studies of targeted anticancer agents have generally used traditional endpoints for selection of the recommended phase II dose. More research is needed to define suitable molecular measures of drug effect and the means to incorporate them in the early drug development process.
- Published
- 2004
- Full Text
- View/download PDF
20. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
- Author
-
Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT, McIntosh LW, Geary RS, and Eisenhauer EA
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma secondary, Adult, Aged, Antineoplastic Agents adverse effects, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Dose-Response Relationship, Drug, Enzyme Inhibitors adverse effects, Female, Humans, Infusions, Intravenous, Isoenzymes antagonists & inhibitors, Isoenzymes genetics, Male, Maximum Tolerated Dose, Middle Aged, Oligodeoxyribonucleotides, Antisense adverse effects, Protein Kinase C antagonists & inhibitors, Protein Kinase C genetics, Protein Kinase C-alpha, Proto-Oncogene Proteins c-raf antagonists & inhibitors, Proto-Oncogene Proteins c-raf genetics, Thionucleotides adverse effects, Treatment Outcome, Adenocarcinoma drug therapy, Antineoplastic Agents therapeutic use, Colorectal Neoplasms drug therapy, Enzyme Inhibitors therapeutic use, Oligodeoxyribonucleotides, Antisense therapeutic use, Thionucleotides therapeutic use
- Abstract
Background: Because treatment of metastatic colon cancer is noncurative, new treatments are needed. This trial evaluated the antitumor effects of two targeted anticancer agents: (a) ISIS 3521, an antisense inhibitor of the protein kinase C alpha; and (b) ISIS 5132, an antisense inhibitor of c-raf kinase in patients untreated previously with recurrent or metastatic colorectal carcinoma., Patients and Methods: All patients had colorectal adenocarcinoma with measurable disease and no prior chemotherapy for metastatic disease. Patients were randomized to receive either ISIS 3521 or ISIS 5132 at a dose of 2 mg/kg/day as a continuous i.v. infusion 21 of 28 days. Cycles were repeated as long as progression was not seen, and doses of both agents were modified according to toxic effects. A two-arm study design was used with each study arm considered independently. Steady-state blood levels of both antisense molecules were measured on days 8, 15, and 22 of the first cycle of therapy., Results: Thirty-seven eligible patients were enrolled, and 32 were evaluable for response (17 receiving ISIS 3521 and 15 receiving ISIS 5132). No responses were noted. Four of the patients receiving ISIS 3521 had stable disease, and 5 patients receiving ISIS 5132 were stable., Conclusion: Neither ISIS 5132 nor ISIS 3521given in the dose and schedule studied induced objective responses in untreated colorectal cancer patients.
- Published
- 2002
21. Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.
- Author
-
Brotto, Lori, Brundage, Michael, Hoskins, Paul, Vergote, Ignace, Cervantes, Andres, Casado, Herraez, Poveda, A., Eisenhauer, Elizabeth, Tu, Dongsheng, Casado, Herraez A, Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group (NCIC CTG), the European Organization for Research and Treatment of Cancer—Gynecologic Cancer Group (EORTC-GCG) and the Grupo de Investigación de Cáncer de Ovario, Gynecologic Cancer Intergroup Study of NCIC Clinical Trials Group (NCIC CTG), European Organization for Research and Treatment of Cancer - Gynecologic Cancer Group (EORTC-GCG), and Grupo de Investigación de Cáncer de Ovario (GEICO)
- Subjects
CISPLATIN ,TOPOTECAN ,CARBOPLATIN ,PACLITAXEL ,OVARIAN cancer ,QUALITY of life ,MENTAL health ,ANTINEOPLASTIC agents ,BODY image ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,OVARIAN tumors ,PROGNOSIS ,QUESTIONNAIRES ,RESEARCH ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,PSYCHOLOGY ,THERAPEUTICS - Abstract
Background: A recent phase III trial compared the efficacy of cisplatin-topotecan (a topoisomerase I inhibitor) followed by carboplatin-paclitaxel (Arm 1) versus paclitaxel-carboplatin (Arm 2) in women with newly diagnosed stage IIB or greater ovarian cancer. There was a significantly lower response rate in the experimental arm compared to standard treatment, and less likelihood of normalized CA125 within the first 3 months. At 43 months follow-up, there were no significant group differences in progression-free survival. There were also significantly more side effects in the experimental arm.Methods: The current study examined quality of life (QoL) endpoints using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and the ovarian cancer module, QLQ-OV28, administered prior to randomization, at day 1 of treatment cycles 3, 5, and 7, at completion of the last cycle, and at 3 and 6 months following completion of chemotherapy.Results: Global QoL, physical symptoms, fatigue, and role, emotional, cognitive and social function (all from the EORTC QLQ-C30) significantly improved in both treatment arms, with no significant between-arm differences. Between-group differences in pain, insomnia, and peripheral neuropathy reported while on treatment did not differ at follow-up. Nausea and vomiting improved more with standard treatment both during and after treatment. Body image significantly differed between the groups only at cycle 5 (more deterioration in Arm 2) but group differences disappeared at follow-up. A stratified analysis of global QoL by debulking surgery status found no greater effect indicating that overall improvements in QoL were unrelated to surgical recovery.Conclusions: There was no significant QoL advantage of cisplatin-topotecan. This finding, combined with no progression-free survival conferred by this combination, reaffirms carboplatin-paclitaxel as the standard of care for women with newly diagnosed ovarian cancer. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
22. Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice.
- Author
-
Parulekar, Wendy R. and Eisenhauer, Elizabeth A.
- Subjects
ANTINEOPLASTIC agents ,CANCER chemotherapy ,TUMOR treatment ,CLINICAL drug trials ,ENZYME inhibitors ,DRUG development ,CLINICAL trials - Abstract
Background: New targeted, non-cytotoxic anticancer agents, such as small-molecule kinase inhibitors, pose challenges to the current phase I paradigm of dose selection based on toxicity. Moreover, increasing the drug dose to toxicity may be unnecessary for drug effect, making the use of maximum tolerated dose as a surrogate of effective dose inappropriate in the phase I setting. Because little is known about the optimal methods of recommended phase II dose selection of targeted, non-cytotoxic therapies, we reviewed the strategies that were used in completed phase I studies of these drugs. Methods: We retrieved 60 publications of phase I studies involving 31 single agents representative of the most common targets of interest in the oncology literature. For each publication, we abstracted data regarding patient population, starting dose, methods of dose escalation and determination of recommended phase II dose, and inclusion of correlative studies in study conduct. Results: Of the 60 completed phase I studies, 36 used toxicity and eight used pharmacokinetics data as endpoints for selection of the recommended phase II dose. Nontraditional endpoints, such as measures of molecular drug effects in tumor or surrogate tissue or functional imaging studies, were not routinely incorporated into the study design and rarely formed the primary basis for dose selection. Conclusions: To date, phase I studies of targeted anticancer agents have generally used traditional endpoints for selection of the recommended phase II dose. More research is needed to define suitable molecular measures of drug effect and the means to incorporate them in the early drug development process. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
23. New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
- Author
-
Therasse, Patrick, Arbuck, Susan G., Eisenhauer, Elizabeth A., Wanders, Jantien, Kaplan, Richard S., Rubinstein, Larry, Verweij, Jaap, Van Glabbeke, Martine, van Oosterom, Allan T., Christian, Michaele C., and Gwyther, Steve G.
- Subjects
CANCER treatment ,ANTINEOPLASTIC agents ,TESTING - Abstract
Investigates anticancer cytotoxic agents. Philosophical background to clarify the various purposes of response evaluation; Model by which a combined assessment of all existing lesions is used to extrapolate an overall response to treatment Other aspects of response evaluation.
- Published
- 2000
- Full Text
- View/download PDF
24. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
- Author
-
Gelmon, Karen A., Eisenhauer, Elizabeth A., Gelmon, K A, Eisenhauer, E A, Harris, A L, Ratain, M J, and Workman, P
- Subjects
- *
CANCER treatment , *ASSOCIATIONS, institutions, etc. , *DRUG development , *ANIMALS , *ANTINEOPLASTIC agents , *CELLULAR signal transduction , *CLINICAL trials , *TUMORS , *INVESTIGATIONAL drugs , *PHARMACODYNAMICS - Abstract
Summarizes the issues discussed at the workshop 10th National Cancer Institute-European Organization for Research and Treatment of Cancer Symposium on New Drugs in Cancer Therapy held in the United States. Preclinical assessment; Phase I trial design of an anticancer drug; Lessons from nononcology drugs.
- Published
- 1999
- Full Text
- View/download PDF
25. Hypersensitivity reactions to deoxycoformycin.
- Author
-
O'Dwyer, Peter, King, Susan, Eisenhauer, Elizabeth, Grem, Jean, Hoth, Daniel, O'Dwyer, P J, King, S A, Eisenhauer, E, Grem, J L, and Hoth, D F
- Subjects
ANTINEOPLASTIC agents ,DRUG allergy ,ENZYME inhibitors ,NUCLEOSIDES ,SKIN ,ALLOPURINOL - Abstract
Deoxycoformycin (dCF) is a promising new antineoplastic agent in the treatment of lymphoid malignancies, particularly hairy cell leukemia (HCL). Skin toxicity in the form of a maculopapular eruption has previously been reported but has not clearly been associated with idiosyncratic reactions. We present five cases of dCF-related hypersensitivity reactions in which additional systemic manifestations indicated an allergic etiology. The value of dCF in treating lymphoid neoplasms suggests that further study of the treatment of these reactions is indicated. [ABSTRACT FROM AUTHOR]
- Published
- 1989
- Full Text
- View/download PDF
26. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
- Author
-
Ledermann, Jonathan A., Embleton, Andrew C., Raja, Fharat, Perren, Timothy J., Jayson, Gordon C., Rustin, Gordon J. S., Kaye, Stan B., Hirte, Hal, Eisenhauer, Elizabeth, Vaughan, Michelle, Friedlander, Michael, González-Martín, Antonio, Stark, Daniel, Clark, Elizabeth, Farrelly, Laura, Swart, Ann Marie, Cook, Adrian, Kaplan, Richard S., Parmar, Mahesh K. B., and ICON6 collaborators
- Subjects
- *
OVARIAN cancer , *DISEASE relapse , *CLINICAL trials , *CANCER chemotherapy , *PLACEBOS , *DISEASE progression , *ANTINEOPLASTIC agents , *CANCER relapse , *COMPARATIVE studies , *HETEROCYCLIC compounds , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *OVARIAN tumors , *RESEARCH , *RESEARCH funding , *EVALUATION research , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *BLIND experiment , *CARBOPLATIN ,EPITHELIAL cell tumors - Abstract
Background: Angiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1-3 inhibitor that has shown antitumour activity in recurrent ovarian cancer. We assessed efficacy and safety of cediranib in combination with platinum-based chemotherapy and as continued maintenance treatment in patients with first relapse of platinum-sensitive ovarian cancer.Methods: In this randomised, three-arm, double-blind, placebo-controlled phase 3 trial, we randomly assigned patients aged 18 years or older with relapsed platinum-sensitive ovarian cancer at 63 centres in Australia, Canada, New Zealand, Spain, and the UK. Participants received up to six cycles of platinum-based chemotherapy (once every 3 weeks) then entered a maintenance phase. Participants were randomly allocated (2:3:3), with five stratification factors and in alternating blocks, to receive placebo alongside chemotherapy and then placebo only maintenance (arm A; reference), cediranib 20 mg once-daily alongside chemotherapy then placebo only maintenance (arm B; concurrent), or cediranib 20 mg once-daily alongside chemotherapy then cediranib 20 mg once-daily maintenance (arm C; maintenance). Patients continued treatment to progression or excessive toxic effects. The primary efficacy endpoint was progression-free survival between arms A and C. Efficacy analysis was by intention to treat. Safety was assessed in all patients who received the allocated study drug. This trial is registered with ClinicalTrials.gov, number NCT00532194; the ISRCTN registry, number ISRCTN68510403; and ANZ Clinical Trials Registry, number ACTRN1261000016003.Findings: We randomly assigned 486 [corrected] women between Nov 13, 2007, and Dec 23, 2011; results presented are for 456 patients randomly assigned subsequent to the 30mg safety phase. During a median of 19·5 months (IQR 14-26) follow-up, 113 (96%) of 118 women assigned to arm A and 141 (86%) of 164 assigned to arm C had disease progression. Median progression-free survival was 11·0 months (95% CI 10·4-11·7) in arm C and 8·7 months (7·7-9·4) in arm A (hazard ratio 0·56, 0·44-0·72, p<0·0001). 156 (90%) of 174 patients in arm B had disease progression, and median progression-free survival was 9·9 months (95% CI 9·4-10·5). Diarrhoea, neutropenia, hypertension, and voice changes were significantly more common, during chemotherapy with cediranib, and diarrhoea, hypothyroidism and voice changes were more common during maintenance. Poor compliance with cediranib was noted during maintenance treatment with toxic effects being the most common cause for discontinuation.Interpretation: Cediranib, when given orally with chemotherapy and continued as maintenance, yielded a meaningful improvement [corrected] in progression-free survival in women with recurrent platinum-sensitive ovarian cancer, albeit with added toxic effects. The positive results in ICON6 could provide women with a new therapeutic option for recurrent ovarian cancer. Assessment of the secondary endpoint of overall survival will need longer follow-up.Funding: Medical Research Council, Cancer Research UK, Canadian Cancer Society Research Institute, Cancer Australia, National Gynecological Cancer Centre, and AstraZeneca. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
27. Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies
- Author
-
Seymour, Lesley K., Calvert, A. Hilary, Lobbezoo, Marinus W., Eisenhauer, Elizabeth A., and Giaccone, Giuseppe
- Subjects
- *
TUMOR classification , *ANTINEOPLASTIC agents , *BIOMARKERS , *TUMORS , *PHARMACODYNAMICS - Abstract
Abstract: The Methodology for the Development of Innovative Cancer Therapies (MDICT) task force considered aspects of the design and conduct of early (phase I and II) studies of combinations of molecular targeted agents during their 2012 meeting. The task force defined necessary non-clinical data, such as evidence of additive or synergistic effects in multiple molecularly credentialed and validated models, and appropriate pharmacodynamic marker development. A robust hypothesis was considered critical while non-clinical pharmacokinetic studies were also considered valuable. Clinical trials should include clear objectives that will prove or disprove the hypothesis. Predictive biomarkers/classifiers should be explored in phase I studies, rather than used to select patients. Trial design should be efficient and flexible rather than based on a strict progression from phase I to II to III; researchers could consider phase I studies with an expansion cohort, Phase I/II designs or phase II studies with a safety run in. Pharmacokinetics are recommended when interactions or overlapping toxicity is expected. Pharmacodynamic evaluations should be considered especially in a subset of patients closest to the recommended dose; an attempt should be made to validate surrogate tissues to enable inclusion for all patients. Schedule and or dose should be formally explored for e.g. with a randomised or an adaptive design. Data and knowledge sharing was strongly recommended, including the creation of formal or informal consortia of laboratories with individual expertise in pathway or target based models, collaboration between companies to ensure that agents which are ‘best in class’ are combined, and the development of databases which will be able to inform the development of future recommendations/guidelines. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.